6.63
0.10 (1.53%)
| Penutupan Terdahulu | 6.53 |
| Jumlah Dagangan | 187,272 |
| Harga / Buku (P/B) | 9.20 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.640 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.93% |
| Nisbah Semasa (MRQ) | 8.02 |
| Aliran Tunai Operasi (OCF TTM) | -22.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.80 M |
| Pulangan Atas Aset (ROA TTM) | -41.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -67.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | DiaMedica Therapeutics Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 26.28% |
| % Dimiliki oleh Institusi | 35.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Omega Advisors Inc. | 30 Jun 2026 | 3,450,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |